A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer

Citrin, Dennis L.; Hogan, Tom F.

doi:10.1002/1097-0142(19820715)50:2<201::aid-cncr2820500205>3.0.co;2-7

Cited by 25 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response criteria used to assess therapeutic effectiveness in prostate cancer are controversial (8,9). The results of our trial failed to identify significant antitumor activity for esorubicin in hormone resistant prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

et al. 1986

View full text Add to dashboard Cite

Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4'-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4'-deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

et al. 1986

View full text Add to dashboard Cite

show abstract

“…For instance, in a Phase II trial of doxorubicin and cisplatin, significant improvements were demonstrated in prostatic acid phosphatase in 21% of patients, and clinical improvement was observed in 24% of patients. 18 Additional trials have combined cisplatin with doxorubicin plus 5-flourouracil, 16 with strontium-89 ( 89 Sr), 22,30 with etoposide plus pirarubicin, 32 with mitoxantrone, 33 with estramustine plus etoposide, 19 and with calcitriol plus dexamethasone. 90 Some regimens have been targeted specifically against small cell carcinoma, with cisplatin and etoposide as the core elements of the regimen.…”

Section: Multiagent Regimens That Include Cisplatin and Carboplatinmentioning

confidence: 99%

“…15 Although earlier studies suggested a lack of activity, more recent studies using palliation and PSA endpoints have suggested a greater degree of clinical benefit. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] In addition, several recent clinical trials have combined carboplatin with taxanes and demonstrated promising results. [34][35][36] Finally, a new platinum analogue, satraplatin, has demonstrated intriguing activity in HRPC and is being tested in a large randomized study in the second-line chemotherapy setting.…”

mentioning

confidence: 99%

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

Tay

Huang

2006

Cancer

View full text Add to dashboard Cite

Docetaxel chemotherapy is the current standard of care for metastatic hormone-refractory prostate cancer (HRPC). Platinum chemotherapy drugs, such as cisplatin and carboplatin, have moderate single-agent activity in HRPC. Next-generation platinum drugs, including satraplatin and oxaliplatin, may have additional activity in the management of HRPC. Furthermore, neuroendocrine differentiation may play a role in disease progression, providing a rationale for platinum-based chemotherapy in the management of HRPC. The authors reviewed the MEDLINE database for reports related to platinum-based chemotherapy in patients with advanced prostate cancer and evaluated studies that reviewed the role of neuroendocrine differentiation in the progression of HRPC. Older studies from the 1970s and 1980s suggested a lack of activity of cisplatin and carboplatin; however, those studies were flawed at least in part by their methods of response assessment. More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However, when carboplatin was combined with a taxane and estramustine, high response rates were observed in several recent clinical trials. In addition, a randomized trial suggested that satraplatin plus prednisone improved progression-free survival compared with prednisone alone. For patients who progressed after docetaxel, no standard options existed in the literature that was reviewed. Several preliminary reports suggested that carboplatin and oxaliplatin may have activity as second-line chemotherapy. Platinum chemotherapy drugs historically have been considered inactive in HRPC, although a review of the data suggested otherwise. Carboplatin, in particular, induced very high response rates when it was combined with estramustine and a taxane, but it also appeared to have activity in patients who progressed after docetaxel. Satraplatin plus prednisone is being investigated in a large Phase III trial as second-line chemotherapy for HRPC. Targeting neuroendocrine cells may provide a new therapeutic approach to HRPC.

show abstract

“…Since ethical considerations prohibit study of a series of untreated controls who failed with hormone therapy, concern about the use of stable as a category is afi issue that cannot be completely resolved, but nevertheless is an important entity in evaluating therapies for, and management of, the patient with advanced disease.' ', [31][32][33][34] It has been pointed out that total response rates of 30% or better have been reported by the NPCP for a number of agents studied in their clinical trials, in which only 2% to 6% of this response rate was made up of objective partial responses.32 Such an argument implies that only partial (or complete) responses have any real meaning or value, supposedly for indicating the efficacy of treatment, which in turn should reflect an improvement in the patient's well-being. The alternate or counter argument, of course, is that stable does not reflect treatment efficacy and/or patient well-being.…”

Section: Age At Entry (Years)mentioning

confidence: 99%

A reexamination of the stable category for evaluating response in patients with advanced prostate cancer

Slack

Brady

Murphy

1984

Cancer

View full text Add to dashboard Cite

Stable response to therapy in patients with advanced prostate cancer, as experienced in clinical trials of the National Prostatic Cancer Project (NPCP) has been re‐examined. Data from 10 completed trials, totaling over 1300 patients, have been examined for survival patterns within categories of response to therapy. Survival patterns, for patients alive at 12 weeks, were significantly poorer for patients who were categorized as progressors after 12 weeks on treatment than for those who were categorized as stable or as partial regressions. Furthermore, comparisons of survival patterns for those patients who were categorized as stable or partial regression revealed no statistically significant differences between them. The concerns over the use of stable as an indicator of response and the problems in establishing its true meaning are discussed. All things considered, the use of stable is a valid means to evaluate the status of patients in clinical trials of treatment modalities for advanced cancer of the prostate.

show abstract

A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer

Cited by 25 publications

References 18 publications

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

A reexamination of the stable category for evaluating response in patients with advanced prostate cancer

Contact Info

Product

Resources

About